The estimated Net Worth of Andrew J. Fromkin is at least $3.53 Million dollars as of 1 December 2023. Mr. Fromkin owns over 12,350 units of Immunovant Inc stock worth over $2,575,515 and over the last 5 years he sold IMVT stock worth over $490,666. In addition, he makes $461,515 as Independent Director at Immunovant Inc.
Andrew has made over 2 trades of the Immunovant Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 12,350 units of IMVT stock worth $490,666 on 1 December 2023.
The largest trade he's ever made was selling 12,350 units of Immunovant Inc stock on 1 December 2023 worth over $490,666. On average, Andrew trades about 1,983 units every 94 days since 2019. As of 1 December 2023 he still owns at least 88,658 units of Immunovant Inc stock.
You can see the complete history of Mr. Fromkin stock trades at the bottom of the page.
Andrew (Drew) J. Fromkin serves as Independent Director of the Company. Since the closing of the Business Combination in December 2019, Mr. Fromkin has served as a member of Immunovant’s board of directors. Since March 2015, Mr. Fromkin has served as Chief Executive Officer of Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.). From 2005 until 2011, Mr. Fromkin served in various roles for Clinical Data, Inc., including Executive Vice President (October 2005 until May 2006), President, Chief Executive Officer and Director (May 2006 until May 2011). Prior to Clinical Data, Mr. Fromkin served as President and Chief Executive Officer of DoctorQuality, Inc., President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. Mr. Fromkin began his career at Health Information Technologies, Inc. as General Manager of its subsidiary, MCA, and Director of Marketing and Payer Alliances for the parent company. From 2014 until 2016, Mr. Fromkin served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015.
As the Independent Director of Immunovant Inc, the total compensation of Andrew Fromkin at Immunovant Inc is $461,515. There are 5 executives at Immunovant Inc getting paid more, with Peter Salzmann having the highest compensation of $8,806,830.
Andrew Fromkin is 54, he's been the Independent Director of Immunovant Inc since 2019. There are 7 older and 8 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
Andrew's mailing address filed with the SEC is 320 W 37TH STREET, 6TH FLOOR, , NEW YORK, NY, 10018.
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann und Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: